Mead Johnson Nutrition (MJN) Stock Price Target Lowered at JPMorgan

NEW YORK (TheStreet) -- Mead Johnson Nutrition (MJN) had its price target lowered to $99 from $111 at JPMorgan Chase which maintained its "overweight" rating.

While the firm continues to believe infant formula will remain one of the best growth categories over time, analysts are concerned about near-term trends in China. 

"In particular, competitive pricing has dropped to levels management sees as 'somewhat irrational'," analysts at JPMorgan said.

Additionally, issues in Hong Kong are likely to hamper sales growth for much of the rest of 2015, the firm added.

Mead Johnson Nutrition is a global pediatric nutrition company that manufactures, distributes and sells infant formulas, children's nutrition and other nutritional products.

Shares of Mead Johnson Nutrition are down 0.26% to $90.71 in morning trading Thursday.

Separately, TheStreet Ratings team rates MEAD JOHNSON NUTRITION CO as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:

"We rate MEAD JOHNSON NUTRITION CO (MJN) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its increase in net income, expanding profit margins, growth in earnings per share, increase in stock price during the past year and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."

If you liked this article you might like

McCormick in $4.2 Billion Play for Reckitt Benckiser's Food Division

Reckitt Wrecked By Petya Virus

Reckitt Benckiser Says Petya Cyber Attack Will Slam Q2 Revenues

Reckitt to Close $18 Billion Mead Johnson Takeover Deal June 15